Home207940 • KRX
add
Samsung Biologics Co Ltd
Nakaraang pagsara
₩1,034,000.00
Sakop ng araw
₩1,015,000.00 - ₩1,040,000.00
Sakop ng taon
₩722,000.00 - ₩1,209,000.00
Market cap
72.53T KRW
Average na Volume
80.03K
P/E ratio
56.68
Dividend yield
-
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (KRW) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 1.30T | 37.11% |
Gastos sa pagpapatakbo | 241.41B | 22.51% |
Net na kita | 375.55B | 109.38% |
Net profit margin | 28.93 | 52.75% |
Kita sa bawat share | 5.28K | 109.40% |
EBITDA | 650.09B | 78.25% |
Aktuwal na % ng binabayarang buwis | 24.80% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (KRW) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 1.29T | -37.61% |
Kabuuang asset | 17.44T | 5.53% |
Kabuuang sagutin | 6.16T | -5.47% |
Kabuuang equity | 11.28T | — |
Natitirang share | 71.17M | — |
Presyo para makapag-book | 6.52 | — |
Return on assets | 7.00% | — |
Return on capital | 9.70% | — |
Cash Flow
Net change in cash
| (KRW) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 375.55B | 109.38% |
Cash mula sa mga operasyon | 682.98B | 135.64% |
Cash mula sa pag-invest | -250.22B | -142.78% |
Cash mula sa financing | -69.80B | 65.49% |
Net change in cash | 360.84B | -47.87% |
Malayang cash flow | -103.14B | -115.61% |
Tungkol
Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb. Wikipedia
CEO
Itinatag
2011
Website
Mga Empleyado
4,770
